Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$15.4 million.

  • CytomX Therapeutics' Free Cash Flow rose 2567.48% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.4 million, marking a year-over-year increase of 1850.71%. This contributed to the annual value of -$86.5 million for FY2024, which is 5216.0% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Free Cash Flow stood at -$15.4 million, which was up 2567.48% from -$15.8 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Free Cash Flow ranged from a high of $9.3 million in Q1 2023 and a low of -$42.0 million during Q1 2022
  • Moreover, its 5-year median value for Free Cash Flow was -$22.2 million (2023), whereas its average is -$22.6 million.
  • Over the last 5 years, CytomX Therapeutics' Free Cash Flow had its largest YoY gain of 12211.94% in 2023, and its largest YoY loss of 131136.51% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Free Cash Flow stood at -$31.4 million in 2021, then surged by 94.99% to -$1.6 million in 2022, then plummeted by 1311.37% to -$22.2 million in 2023, then increased by 10.08% to -$20.0 million in 2024, then increased by 22.85% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q3 2025, -$15.8 million for Q2 2025, and -$21.2 million during Q1 2025.